Bayer's Pipeline Just Delivered Twice in Three Days — Now Comes the Hard Part

Bayer packed two regulatory and clinical milestones into a single weekend, and by Monday the market had already voted. Yet the more instructive question for investors isn't whether the news was good — it plainly was — but how much of it can be converted into booked business, and how much remains promise.

JPMorgan's Richard Vosser came down firmly on the optimistic side. According to media reports, the analyst kept his "Overweight" rating and a price target of 61 euros on the German life-sciences group, arguing that the interim results from the DASL-HiCaP trial underpin his view that consensus expectations are set too low. Darolutamid paired with radiotherapy, he suggested, could become an additional growth engine for Nubeqa in patients facing a very high risk of recurrence.

What the data showed

The evidence Vosser is leaning on arrived on Saturday, when Bayer published an interim analysis of the Phase III DASL-HiCaP study. Adding darolutamid to androgen deprivation therapy and radiotherapy cut the risk of metastases or death by 58 percent versus placebo in prostate-cancer patients at high risk of relapse. The four-year metastasis-free survival rate came in at 95 percent, against 88 percent for the control arm.

Those figures carry weight because they track hard outcomes — the emergence of metastases or death — rather than a single laboratory marker. What they do not yet carry is a label. Darolutamid is not approved for this particular treatment setting, so the path from encouraging data to a commercially usable indication still runs through regulators.

Should investors sell immediately? Or is it worth buying Bayer?

A world-first, with borders

Two days later came a decision of a different kind. China's NMPA granted Asundexian its first marketing authorization anywhere, under the brand name Sunharbo. The approval covers reducing stroke risk in adults following a non-cardioembolic ischemic stroke or a high-risk TIA. Bayer describes the compound as the world's first approved factor XIa inhibitor.

The scope matters as much as the milestone. The green light applies to China and to the patient groups named in the label — it does not imply approval elsewhere or a broader use case. Nor does a regulatory decision equal a revenue contribution. The first-approved-in-class status is a genuine scientific and regulatory advance; it is not, on its own, proof of demand.

Exchange reports attributed Monday's share-price gain to the two pharmaceutical announcements taken together.

Elsewhere in the medicine cabinet

The pipeline news extended beyond those headlines. On October 22, at ASN Kidney Week, Bayer presented further analyses from the FIND-CKD study. Finerenon showed consistent effects on proteinuria and a slowing of kidney-function loss across several patient groups with chronic kidney disease without diabetes, according to the company.

Separately, subsidiary Vividion Therapeutics has launched a global Phase II trial of the WRN inhibitor VVD-214 in combination with pembrolizumab. The study targets previously untreated patients with advanced MSI-H or dMMR colorectal carcinoma, and the first patient has already been dosed, Bayer said.

The distinction that should anchor the thesis

The constructive case does not require treating the two main announcements as equivalent. They can complement each other: Asundexian already holds an approval in China, while darolutamid opens a potential additional treatment avenue. Together they could broaden the base for future business opportunities.

Bayer at a turning point? This analysis reveals what investors need to know now.

The risk sits at the opposite extreme — pricing clinical efficacy as if it were already future profit. That leap skips the distance between a trial result, an approval and commercial traction. For darolutamid, the evidence is interim, and the missing authorization applies specifically to the setting under study. For Asundexian, the "world's first" framing describes a regulatory step forward, not a fixed level of demand or a settled economic outcome.

A decision on darolutamid in the studied indication looms as the next concrete regulatory catalyst; a positive ruling would materially change its status relative to today's data. Until then, the potential extra business is best treated as an opportunity rather than a secured contribution — and Asundexian's valuation will be measured by whether its Chinese approval gains commercial weight.

Bayer publishes its quarterly statement for the third quarter of 2026 on November 3, when it will present the results.

Ad

Bayer Stock: New Analysis - 28 October

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...